NCT04157192Completed
Brain Connectome for Acupuncture-treated Migraine Patients
Brain Connectome for Migraine Patients Treated Via Acupuncture: A Randomized, Controlled Study Under Single-blind Conditions, With a Placebo Group and Magnetic Resonance Imaging (MRI)
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
Acupuncture has been a means of treating headaches and migraine since 2002 and is now a World Health Organisation-recognized prophylactic treatment for migraine. Brain activation/de-activation via acupuncture modifies the haemodynamic responses in the brain which may impact the sensorial, cognitive and affective dimensions of pain. Randomized studies on patients suffering from aura-free migraine have shown that the painkilling effect of regular acupuncture sessions on the cerebral substratum, compared with simulated sham-type acupuncture, can reduce the frequency of bouts of migraine, number of days with headaches and also their intensity. Modifications to the white matter (WM) and grey matter (GM) occur after repeated sessions of acupuncture treatment for pain and these are observable via magnetic resonance imaging (MRI). It is a very sensitive technique and often used to detect functional and structural brain changes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 6 Nov 2019
- Start date
- 27 May 2022
- Primary completion date
- 24 Apr 2025
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Diseases
- Migraine
- NCT number
- NCT04157192
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 27 May 2022 to the primary completion date, 24 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All patient who have received botulinum toxin in the past year
Other illness
- All patients with migraine which is secondary to a neurological, neuropsychiatric, or vascular disorder
- All patients suffering from diabetes
- All patients with a past history of alcohol or drug abuse
Other
- All patients with contraindications for an MRI scan
- All patients on antidepressants or Botox.
- All patients already taking part in Category 1 research involving the human person
- All patients on an exclusion period determined by another study
- All patients placed under judicial protection, guardianship, or supervision
- All patients for whom it is impossible to give the subject clear information
- All patients who are pregnant, about to give birth or breastfeeding
- All patient who have undergone antidepressant treatment in the last 2 months
- All patient who have started a background migraine treatment for less than 3 months
- All patient who have more than 14 migraine days per month
Who the study is looking for
- All patients with two to eight bouts of migraine without an aura per month
- All patient aged (≥) 18 to (≤) 60 years old
- All patients who have not had a bout of migraine in the last 24 hours
- All patients who have given free informed consent and have signed the consent form.
- All patients who are affiliated to or beneficiaries of a health insurance scheme
- All patients available for a two-month follow-up
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nîmes Coordinator of this site? Confirm its status | Nîmes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.